Intranasal glucocorticosteroids for the complex treatment of patients with chronic diseases of the nose and paranasal sinuses

Intriduction. Chronic rhinitis and rhinosinusitis noticeably deteriorate the patients’ quality of life and lead to the accompanying upper airway pathology development. The main purpose of treatment of this group of patients is to decrease severity of symptoms and the second one to prevent complications. The optimal therapy will help patients to maintain their lifestyle. Intranasal glucocorticosteroids are first-line drugs to treat acute rhinosinusitis or exacerbations of chronic rhinosinusitis in adults (including the elderly) and adolescents aged 12 years and older as an auxiliary therapeutic agent if treated by antibiotics, and to treat acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection. In the number of trials, mometasone furoate effectiveness in regard to decreasing of prominent symptoms with no side effects development has been shown.

Objective: this article reviews available data on the effectiveness of intranasal corticosteroids – mometasone furoate – in the treatment of different forms of chronic inflammatory diseases of the nose and paranasal sinuses.

Methods: information for this review was identified through a RISC and MEDLINE databases applying key words.

Conclusions: based on the available data, treatment of chronic rhinosinusites and rhinitis should be initiated by conservative therapy. Summarizing information from the available literature we can conclude that treatment by mometasone furoate improve quality of life decreasing clinical symptoms of chronic rhinosinusitis and rhinitis.

1. Stevens W.W., Schleimer R.P., Kern R.C. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016;4(4):565–572. doi: 10.1016/j.jaip.2016.04.012.

2. Johansson L., Akerlund A., Holmberg K., Melén I., Bende M. Prevalence of nasal polyps in adults: the Skovde population based study. Annals of Otology, Rhinology, and Laryngology. 2003;112(7):625–629. doi: 10.1177/000348940311200709.

3. Lange B., Holst R., Thilsing T., Baelum J., Kjeldsen A. Quality of life and associated factors in persons with chronic rhinosinusitis in the general population. Clinical Otolaryngology. 2013;38(6):474–480. doi: 10.1111/coa.12189.

4. Koc C., Arikan O.K., Atasoy P. Aksoy A. Prevalence of Helicobacter pylori in patients with nasal polyps: a preliminary report. Laryngoscope. 2004;114(11):1941–1944. doi: 10.1097/01.mlg.0000147924.96980.34.

5. Larsen P., Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114(4):710–719. doi: 10.1097/00005537- 200404000-00022.

6. Greisner W.A., Settipane G.A. Hereditary factor for nasal polyps. Allergy and Asthma Proceedings 1996;17(5):283–286. doi: 10.2500/108854196778662192.

7. Molnar‐Gabor E., Endreffy E., Rozsasi A. HLA‐DRB1, ‐DQA1, and ‐DQB1 genotypes in patients with nasal polyposis. Laryngoscope 2000;110(3 Pt 1):422–425. doi: 10.1097/00005537-200003000-00017.

8. Rugina M., Serrano E., Klossek J.M., Crampette L., Stoll D., Bebear J.P. et al. Epidemiological and clinical aspects of nasal polyps in France: the ORLI group experience. Rhinology 2002;40(2):75–79. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12091997.

9. Chin D., Harvey R.J. Nasal polyposis: an inflammatory condition requiring effective anti‐inflammatory treatment. Current Opinion in Otolaryngology Head & Neck Surgery. 2013;21(1):23–30. doi: 10.1097/MOO.0b013e32835bc3f9.

10. Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology. 2012;23:1–298. doi: 10.4193/Rhino50E2.

11. Arefieva N.A., Vishnyakov V.V., Ivanchenko O.A., Lopatin A.S. (ed.) Chronic rhinosinusitis: pathogenesis, diagnosis and treatment principles: clinical rec­ ommendations. Russian society of rhinologists. Moscow: Practical medicine; 2014. 64 p. (In Russ.) Available at: https://www.osp.ru/netcat_files/userfiles/lvrach/Sinusit-recommendations.pdf.

12. Hellings P.W. Implementing precision medicine in best practices of chronic airway diseases. Endotype­Driven Approach in Rhinitis. 2019;149(6):802– 803. doi: 10.4103/ijmr.IJMR_608_19.

13. Kaliner M.A. Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic rhinopathy. World Allergy Organiz J. 2009;2(6):98–101. doi: 10.1097/WOX.0b013e3181a9d55b.

14. Mølgaard E., Thomsen S.F., Lund T., Pedersen L., Nolte H., Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. Allergy. 2007;62(9):1033–1037. doi: 10.1111/j.1398-9995.2007.01355.x.

15. Kaliner M.A. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). J Allergy Clin Immunol. 2011;31(3):441–455. doi: 10.1016/j.iac.2011.05.007.

16. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A. et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):S1–S84. doi: 10.1016/j.jaci.2008.06.003.

17. Brożek J.L., Bousquet J., Agachee I., Agarwal A., Bachert C., Bosnic- Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol. 2017;140(4):950–958. doi: 10.1016/j.jaci.2017.03.050.

18. Roxbury C.R., Qiu M., Shargorodsky J., Lin S.Y. Association between allergic rhinitis and poor sleep parameters in US adults. Int International forum of allergy & rhinology. 2018;8(10):1098–1106. doi: 10.1002/alr.22174.

19. Robinson S., Buchs S., Hammerby E., Kennedy-Martin T. A Review of The Quality of Life and Educational Burden of Allergic Rhinitis on Adolescents. Value in Health. 2017;20(9):PA648. doi: 10.1016/j.

20. Lal D., Hwang P.H. Oral corticosteroidtherapy in chronic rhinosinusitis without polyposis: a systematic review. Int. Forum Allergy Rhinol. 2011;1(2):136–143. doi: 10.1002/alr.20024.

21. Snidvongs K., Kalish L., Sacks R., Craig C.J., Harvey J.R. Topical steroid for chronic rhinosinusitis without polyps. Cochrane Database Syst Rev. 2011;(8):CD009274. doi: 10.1002/14651858.CD009274.

22. Bachmann G., Hommel G., Michel O. Effect of irrigation of the nose with isotonic salt solution on adult patients with chronic paranasal sinus disease. Eur. Arch. Otorhinolaryngol. 2000;257(10):537–541. doi: 10.1007/s004050000271.

23. Harvey R., Hannan S.A., Badia L., Scadding G. Nasal saline irrigations for the Symptoms of chronic rhinosinusitis. Cochrane Database Syst Rev. 2007;(3):CD006394. doi: 10.1002/14651858.CD006394.pub2.

24. Videler W.J., van Drunen C.M., Reitsma J.B., Fokkens W.J. Nebulized bacitracin/colimycin: a treatment option in recalcitrant chronic rhinosinusitis with Staphylococcus aureus? A double-blind, randomized, placebo-controlled, cross-overpilot study. Rhinology. 2008;(2):92–98. Available at: https://www.ncbi.nlm.nih.gov/pubmed/18575008.

25. Uren B., Psaltis A., Wormald P.J. Nasallavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope. 2008;118(9):1677–1680. doi: 10.1097/MLG.0b013e31817aec47.

26. Kaliner M.A. Nonallergic rhinopathy (formerly known as vasomotor rhinitis). Immunol Allergy Clin North Am. 2011;31(3):441–455. doi: 10.1016/j.iac.2011.05.007.

27. Schroer B., Pien L.C. Nonallergic rhinitis: common problem, chronic symptoms. Cleve Clin J Med. 2012;79(4):285–293. doi: 10.3949/ccjm.79a11099.

28. Platts-Mills T.A., Vervloet D., Thomas W.R., Aalberse R.C., Chapman M.D. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol. 1997;100(6):2–24. doi: 10.1016/s00916749(97)70292-6.

29. Piacentini G.L., Martinati L., Mingoni S., Boner A.L. Influence of allergen avoidance on the eosinophil phase of airway inflammation in children with allergic asthma. J Allergy Clin Immunol. 1996;97(5):1079–1084. doi: 10.1016/S0091-6749(96)70261-0.

30. Sharma H.P., Hansel N.N., Matsui E., Diette G.B., Eggleston P., Breysse P. Indoor environmental influences on children’s asthma. Pediatric Clinics of North America. 2007;54(1):103–120. doi: 10.1016/j.pcl.2006.11.007

31. Platts-Mills T.A. Allergen avoidance in the treatment of asthma and allergic rhinitis. New England Journal of Medicine. 2003;349(3):207–208. doi: 10.1056/NEJMp030082.

32. Maloney J., Bernstein D.I., Nelson H., Creticos P., Hébert J., Noonan M. et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–153.e2. doi: 10.1016/j.anai.2013.11.018.

33. Creticos P.S., Maloney J., Bernstein D.I., Casale T., Kaur A., Fisher R. et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131(5):1342–1349.e6. doi: 10.1016/j.jaci.2013.03.019.

34. Wheatley L.M., Togias A. Allergic rhinitis. N Engl J Med. 2015;372(5):456– 463. doi: 10.1056/NEJMcp1412282.

35. Small P., Kim H. Allergic rhinitis. Allergy, Asthma & Clinical Immunology. 2011;7(Suppl. 1):3. doi: 10.1186/1710-1492-7-S1-S3.

36. Yanez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89(5):479–484. doi: 10.1016/S1081-1206(10)62085-6.

37. Wallace D.V., Dykewicz M.S., Bernstein D.I. et al. Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2 Suppl):1– 84.. doi: 10.1016/j.jaci.2008.06.003.

38. Pullerits T., Praks L., Ristioja V. Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(6):949–955. doi: 10.1067/mai.2002.124467.

39. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317(7173):1624–1629. doi: 10.1136/ bmj.317.7173.1624.

40. Orlandi R., Kingdom T., Hwang P., Smith T., Alt J., Baroody F. et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–S209. doi: 10.1002/alr.21695.

41. Kalish L., Snidvongs K., Sivasubramaniam R., Cope D., Harvey R.J. Topical steroids for nasal polyps. Cochrane Database of Syst Rev. 2012;(12):CD006549. doi: 10.1002/14651858.CD006549.pub2.

42. Slavin R.G. Nasal polyps and sinusitis. JAMA 1997;278(22):1849–1854. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9396646.

43. Sastre J. Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22448448.

44. Szefler S.J. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1 Suppl):26–31. doi: 10.1067/mai.2001.115563.

45. Price D., Kemp L., Sims E., von Ziegenweidt J., Navaratnam P., Lee A.J., Chisholm A., Hillyer E.V., Gopalan G. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J. 2010;19(3):266–273. doi: 10.4104/pcrj.2010.00040.

46. Dalgic A., Dinc M.E., Ulusoy S., Dizdar D., Is A., Topak M. Comparison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):213–216. doi: 10.1016/j.anorl.2016.05.012.

47. Mak K.K., Ku M.S., Lu K.H., Sun H.L., Lue K.H. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol. 2013;54(4):239–245. doi: 10.1016/j.pedneo.2013.01.007.

48. Igarashi T., Nakazato Y., Kunishige T., Fujita M., Yamada Y., Fujimoto C., Okubo K., Takahashi H. Mometasone furoate nasal spray relieves the ocular symptoms of seasonal allergic rhinoconjunctivitis. J Nippon Med Sch. 2012;79(3):182–189. doi: 10.1272/jnms.79.182.

49. Hadley J.A., Derebery J.M., Marple B.F. Comorbidities and allergic rhinitis: not just a runny nose. J Fam Pract. 2012;61(2 Suppl):S11–S15. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22312619.

50. Small P., Frenkiel S., Becker A., Boisvert P. Rhinitis: A practical and comprehensive approach to assessment and therapy. Journal of Otolaryngology. 2007;36(1);5–27. doi: 10.2310/7070.2006.X002.

51. Demoly P. Safety of intranasal corticosteroids in acute rhinosinusitis. Am J Otolaryngol. 2008;29(6):403–413. doi: 10.1016/j.amjoto.2007.11.004.

52. Berlucchi M., Pedruzzi B. Intranasal Mometasone Furoate for treatment of allergic rhinitis. Therapeutics. 2010;2:761–769. doi: 10.4137/CMT.S4767.

53. Baena-Cagnani C.E., Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin. 2010;26(9):2047–2055. doi: 10.1185/03007995.2010.487661.

54. Durr D.G., Desrosiers M. Evidence-based endoscopic sinus surgery. J Otolaryngol. 2003;32(2):101–106. doi: 10.2310/7070.2003.37123.